2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Emerging Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Pathogenesis, Immune Mechanism, Multi-Systemic Interactions, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

2413 In vivo lentiviral dual BCMA/GPRC5D CAR-T therapy GT860 demonstrates T cell-selective engineering, robust CAR expansion, and early clinical activity in multiple myeloma

Pin Wang, PhD, Xianchao Ding2, Zhenzhen Wang3, Jingwei Sun4, Jiahui Jin5, Jingman Wang6, Yiyang Tan7, Zhao Xu8, Haibao Li9, Xiaoling Yun10, Zhiyang Xu11, Lihua Yan12, Wei Xu13, Yin Cheng14, Yarong Liu15
1 Grit Biotherapeutics, Shanghai, China, University of Southern California, Los Angeles, California, United States
2 Yihe Hospital, Henan, China
3 Yihe Hospital, Henan, China
4 Grit Biotherapeutics, Shanghai, China
5 Grit Biotherapeutics, Shanghai, China
6 Grit Biotherapeutics, Shanghai, China
7 Grit Biotherapeutics, Shanghai, China
8 Grit Biotherapeutics, Shanghai, China
9 Grit Biotherapeutics, Shanghai, China
10 Grit Biotherapeutics, Shanghai, China
11 Yihe Hospital, Henan, China
12 Yihe Hospital, Henan, China
13 Yihe Hospital, Henan, China
14 Grit Biotherapeutics, Shanghai, China
15 Grit Biotherapeutics, Shanghai, China

Background:

Direct in vivo generation of CAR-T cells may provide a streamlined alternative to conventional ex vivo manufacturing. GT860 is a T-cell-targeted lentiviral therapy for multiple myeloma (MM) designed to selectively transduce T cells in vivo to express a dual BCMA/GPRC5D CAR. This approach aims to enable sustained CAR expression and broader control of antigen-heterogeneous disease.

Methods:

Preclinical studies evaluated GT860 T-cell selectivity, CAR expression kinetics, dual-antigen cytotoxicity, in vivo CAR-T expansion and persistence, antitumor activity, biodistribution, and safety in human PBMC-based assays and a tumor-bearing PBMC-humanized NOG mouse model. GT860 subsequently entered an ongoing phase 1 dose-escalation study in patients with MM to assess safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity.

Results:

GT860 was developed using a proprietary, demand-driven AI-guided engineering approach to optimize the T-cell binder and fusogen, enabling potent and selective T-cell transduction without exogenous pre-activation. Compared with a clinical benchmark binder, the GT860 binder produced higher and more sustained CAR expression, resulting in an approximately 3-fold increase in CAR-expression AUC in PBMCs from healthy donors and patients with MM. In vitro, GT860 demonstrated cytotoxicity comparable to the clinical benchmark against BCMA-positive tumor cells and superior cytotoxicity against BCMA-negative/GPRC5D-positive tumor cells. In tumor-bearing PBMC-humanized NOG mice, a single GT860 dose generated clinical relevant level of dual-CAR+ T cells (~1×105 /mL) and eradicated tumor growth at both dose levels tested, with minimal induction of IL-6 and TNF-α. At study endpoint, CAR-positive T cells were enriched in bone marrow, spleen, and lung relative to peripheral blood, supporting tissue trafficking and persistence. Histopathology at the high dose showed no treatment-related pathological findings or evidence of oncogenic or tumorigenic effects. A robust, scalable CMC process was established to manufacture clinical-grade GT860 with consistently high product quality.

 As of the data cutoff, 3 patients had received a single GT860 infusion without lymphodepletion, including 2 patients at 2×108TU and 1 at 6×108 TU. Peripheral-blood CAR transgene levels expanded rapidly after Day 10, reaching a Cmax of 6,225 copies/μg gDNA at Day 14 and remaining detectable through Day 28, the latest assessment. At month 1, CAR copy numbers in bone marrow exceeded those in peripheral blood in all three patients. Dual-CAR expression was preferentially detected in CD3-positive T cells, with minimal expression in CD14-positive monocytes and CD19-positive B cells. CAR-T expansion was accompanied by a marked decline in soluble BCMA levels by Day 28. GT860 demonstrated a favorable safety profile, with no grade ≥3 CRS, no ICANS or infusion-related reactions observed. Two of three patients did not develop CRS. One patient experienced Grade 1–2 CRS at peak CAR expression, potentially related to tumor lysis. Other adverse events, including cytopenias and transient elevations in liver enzymes, were generally consistent with the established safety profile of autologous CAR-T therapies, with no unexpected safety signals identified. All 3 patients achieved MRD negativity at a sensitivity of 10-5. Patient 1 achieved a complete response in extramedullary disease. Patient 3 achieved partial responses in both extramedullary and medullary disease. Patient 2 achieved a minimal response in medullary disease, with overall imaging response assessment ongoing at the data cutoff.

Conclusions:

GT860 generate dual BCMA/GPRC5D CAR-T cells in vivo, with robust expansion, potent dual-antigen tumor control and tissue infiltration and persistence in preclinical models, while maintaining a favorable preclinical safety profile. Early clinical data demonstrated T cell-selective transduction, robust CAR expansion, pharmacodynamic activity, manageable safety profile, and encouraging depth of response. These findings support continued dose escalation and development of GT860 as a scalable in vivo dual-target CAR-T therapy for MM.

Pin Wang, PhD: Grit Biotherapeutics - Current Employment